NCT01553851已完成2 期
A Phase II Window of Opportunity Trial With GSK1120212 in Surgically Resectable Oral Cavity Squamous Cell Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- Number of Participants With Changes in Putative Tumor Initiating Cell Populations as Defined by Cell Surface CD44 and Intracellular Phospho-ERK1/2 Staining After Treatment With GSK1120212.
研究概览
简要总结
This phase II trial studies how trametinib effects tumor cells in patients with oral cavity squamous cell carcinoma that can be removed by surgery. Trametinib may shrink the tumor by blocking an enzyme pathway needed for cell growth.
详细描述
The rationale for this study in oral cavity squamous cell carcinomas rests on pre-clinical findings demonstrating that (a) activation of the ERK1/2 kinases is associated with aggressive features, (b) this aggressive phenotype is directly linked to expression of CD44, a cell surface hyaluronan receptor and (c) this association between activated ERK1/2 and CD44 is also identified in human cell lines and primary tumors. These data suggest that ERK1/2 is targetable biochemical pathway in CD44 expressing cells. These cells represent putative cancer stem cells or tumor initiating cells that have been associated with worse patient outcomes. Thus, the application of GSK1120212 to target OCSCC is a specific translational application of our laboratory findings.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient must have histologically or cytologically confirmed oral cavity squamous cell carcinoma of stage 2, 3, 4a, or 4b.
- •Patients by definition have disease at the primary tumor site of at least 2 centimeters.
- •Patient's treatment plan must include primary tumor site biopsy followed by gross excision of the primary tumor site at a separate operative procedure.
- •Patients with concurrent primary head and neck tumors that will be resected as part of treatment plan are considered eligible
- •Patients with head and neck cancer recurrence requiring surgery with no history of prior chemotherapy or radiation therapy are considered eligible.
- •Patient must be ≥ 18 years of age.
- •Patient must have an ECOG performance status ≤ 1
- •Patient must have normal bone marrow and organ function as defined below:
- •Absolute neutrophil count ≥1,200/mcl
- •Hemoglobin ≥9.0 g/dL
- •Platelets ≥100,000/mcl
- •PT/INR and PTT ≤1.3 x IULN (Subjects on Coumadin are included if their coagulation is within a normal therapeutic range)
- •LVEF ≥ILLN (by ECHO or MUGA)
- •Albumin ≥2.5 g/dL
- •Total bilirubin ≤1.5 x IULN
- •AST(SGOT)/ALT(SGPT) ≤2.5 x IULN
- •Creatinine ≤1.5 x IULN OR Creatinine clearance ≥50 mL/min/1.73 m2 for patients with creatinine levels above institutional normal
- •Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control, intrauterine device, male partner sterilization, or complete abstinence) prior to study entry, for the duration of study participation, and for at least 4 months after the last dose of study treatment. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately.
- •Patient must have the ability to swallow and retain orally administered medication.
- •Patient (or legally authorized representative if applicable) must be able to understand and willing to sign an IRB approved written informed consent document.
- •Both men and women and members of all races and ethnic groups are eligible for this trial.
排除标准
- •Patients must not have had any prior head and neck cancer treatment.
- •Patient must not have a history of other malignancy ≤ 3 years previous with the exception of previous head and neck cancer treated only by surgery basal cell or squamous cell carcinoma of the skin which were treated with local resection only or carcinoma in situ of the cervix.
- •Patients must not be receiving any other investigational agents.
- •Patient must not have a history of retinal vein occlusion (RVO).
- •Patient must not have known symptomatic leptomeningeal or brain metastases or spinal cord compression.
- •Patient must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to GSK1120212 or other agents used in the study.
- •Patient must not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowels.
- •Patient must not have an uncontrolled intercurrent illness including, but not limited to, ongoing or active infection symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- •Patient must not be pregnant and/or breastfeeding.
- •Patient must not be known to be HIV-positive, hepatitis B-positive, or hepatitis C-positive (with the exception of chronic or cleared HBV or HCV infection, which will be allowed).
- •Patient must not be taking any herbal supplements during the study (including but not limited to St. John's wort, kava, ephedra (ma huang), gingko biloba, dehydroepiandrosterone (DHEA), yohimbe, saw palmetto, or ginseng). If a potential patient is taking any herbal supplements, s/he must discontinue prior to beginning study treatment.
- •Patient must not have any history or evidence of cardiovascular risk including any of the following:
- •QTcB ≥ 480 msec
- •History or evidence of current clinically significant uncontrolled arrhythmias (exception: subjects with controlled atrial fibrillation for > 30 days prior to registration are eligible)
- •History of acute coronary syndromes (including myocardial infarction and unstable angina), coronary angioplasty, or stenting within 6 months prior to registration
- •History or evidence of current ≥ Class II congestive heart failure as defined by New York Heart Association.
- •Abnormal cardiac valve morphology (≥ grade 2) documented by echocardiogram (subjects with grade 1 abnormalities [i.e., mild regurgitation/stenosis] can be entered on study). Subjects with moderate valvular thickening should not be entered on study.
- •Treated refractory hypertension defined as a blood pressure of systolic >140 mmHg and/or diastolic >90 mmHg which cannot be controlled by antihypertensive therapy.
- •Intra-cardiac defibrillator or permanent pacemaker
- •Cardiac metastases
- •Patient must not have a history of interstitial lung disease or pneumonitis
- •Current use of a prohibited medication
研究组 & 干预措施
GSK1120212
Experimental
GSK1120212 2 mg PO daily for a total of 14 days with the intent of the last pill being the day before surgery.
干预措施: GSK1120212 (Drug)
结局指标
主要结局
Number of Participants With Changes in Putative Tumor Initiating Cell Populations as Defined by Cell Surface CD44 and Intracellular Phospho-ERK1/2 Staining After Treatment With GSK1120212.
时间窗: Baseline and Day 15
Pre-post measure of p-EKP expression was measured by change in staining intensity and quartile distribution.
Number of Participants With Changes in TumorCell Surface CD44 Expression After Treatment With GSK1120212.
时间窗: Baseline and Day 15
Pre-post measure of CD44 expression using IHC.
次要结局
- Tumor Specific Findings for Pathologic Changes Including Proliferation (Ki-67 Staining), Tumor Vasculature Staining (Microvessel Density), ERK1/2 Mediated Changes in p27 (Kip1) & Flow Cytometric Analysis of the Peripheral Blood & Tumor.(Baseline and Day 15)
- Percent of Participants With Metabolic Changes in OCSCC Using FDG-PET/CT Imaging.(Baseline and Day 14)
- Percentage of Participants With Clinical Response Induced by GSK1120212, as Determined by Change in Tumor Size.(Baseline and Day 15)
- Flow Cytometric Analysis of the Peripheral Blood and Tumor.(Baseline, Day 14, and Day 15)
- Percent Change in Maximum Standard Uptake Value in Oral Cavity Saqumous Cell Carcinoma (OCSCC) Using F18-Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography (FDG-PET/CT).(Baseline and Day 14)
- Safety of GSK1120212(1st 4-6 week follow-up visit)
- Percent Change in Tumor Size Area(Baseline and Day 15)
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
2 期
A Phase II Study of Advanced Salivary Gland Carcinoma Based on Molecular TypingAdvanced Salivary Gland CarcinomaNCT05924256Fudan University88
招募中
不适用
Dose De-escalation and Sentinel LN Mapping Driven Radiotherapy of Contralateral Neck in Ipsilateral Node Positive HNSCCSquamous Cell Carcinoma of Head and NeckNCT04688528Universitaire Ziekenhuizen KU Leuven147
终止
2 期
Trametinib in Patients With Advanced Neurofibromatosis Type 1 (NF1)-Mutant Non-small Cell Lung CancerNon-small Cell Lung CancerNCT03232892University of California, San Francisco1
招募中
2 期
Tirelizumab in Combination With Carboplatin and Albumin-binding Paclitaxel for Neoadjuvant Therapy in HNSCCHead and Neck Squamous Cell CarcinomaOral CancerNCT05941338Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University100
已完成
2 期
Gemcitabine in Treating Patients With Advanced Salivary Gland Cancer That Cannot Be Removed During SurgeryHead and Neck CancerNCT00003744Dana-Farber Cancer Institute16